What is the optimal sequence of systemic therapy for a patient with HR+, gBRCA mutated metastatic breast cancer?

The optimal sequencing of HR positive and BRCA germline positive patients has not been established yet in prospective trials. Studies evaluating PARP inhibitors (either single agent or in combination with chemotherapy) versus chemotherapy included patients with HR positive disease, many of whom rece...